D
Kymera Therapeutics, Inc.
KYMR
$22.27
-$1.42-5.99%
D
Sell
4/25/2024Upgraded
Kymera Therapeutics, Inc. (KYMR) was upgraded to D- from E+ on 4/25/2024 due to a significant increase in the growth index, total return index and volatility index. Total revenue increased 912.8% from $4.73M to $47.89M, operating cash flow increased 125.42% from -$31.65M to $8.05M, and earnings per share increased from -$0.9049 to -$0.2455.
Kymera Therapeutics, Inc. (KYMR) was upgraded to D- from E+ on 4/25/2024 due to a significant increase in the growth index, total return index and volatility index. Total revenue increased 912.8% from $4.73M to $47.89M, operating cash flow increased 125.42% from -$31.65M to $8.05M, and earnings per share increased from -$0.9049 to -$0.2455.
E
Sell
2/15/2024Downgrade
Kymera Therapeutics, Inc. (KYMR) was downgraded to E+ from D- on 2/15/2024 due to a decline in the valuation index and growth index.
Kymera Therapeutics, Inc. (KYMR) was downgraded to E+ from D- on 2/15/2024 due to a decline in the valuation index and growth index.
D
Sell
1/31/2024Upgraded
Kymera Therapeutics, Inc. (KYMR) was upgraded to D- from E+ on 1/31/2024 due to an increase in the volatility index, total return index and solvency index.
Kymera Therapeutics, Inc. (KYMR) was upgraded to D- from E+ on 1/31/2024 due to an increase in the volatility index, total return index and solvency index.
E
Sell
1/16/2024Downgrade
Kymera Therapeutics, Inc. (KYMR) was downgraded to E+ from D- on 1/16/2024 due to a noticeable decline in the growth index, solvency index and volatility index. Total revenue declined 71.37% from $16.51M to $4.73M, earnings per share declined from -$0.6652 to -$0.9049, and EBIT declined 32.56% from -$43.38M to -$57.51M.
Kymera Therapeutics, Inc. (KYMR) was downgraded to E+ from D- on 1/16/2024 due to a noticeable decline in the growth index, solvency index and volatility index. Total revenue declined 71.37% from $16.51M to $4.73M, earnings per share declined from -$0.6652 to -$0.9049, and EBIT declined 32.56% from -$43.38M to -$57.51M.
D
Sell
3/14/2023Downgrade
Kymera Therapeutics, Inc. (KYMR) was downgraded to D- from D on 3/14/2023 due to a decline in the solvency index and valuation index.
Kymera Therapeutics, Inc. (KYMR) was downgraded to D- from D on 3/14/2023 due to a decline in the solvency index and valuation index.
D
Sell
2/23/2023Upgraded
Kymera Therapeutics, Inc. (KYMR) was upgraded to D from D- on 2/23/2023 due to an increase in the valuation index, volatility index and total return index.
Kymera Therapeutics, Inc. (KYMR) was upgraded to D from D- on 2/23/2023 due to an increase in the valuation index, volatility index and total return index.
D
Sell
2/8/2023Downgrade
Kymera Therapeutics, Inc. (KYMR) was downgraded to D- from D on 2/8/2023 due to a decline in the growth index and valuation index. Total revenue declined 17.05% from $11.51M to $9.55M, EBIT declined 9.98% from -$40.81M to -$44.88M, and earnings per share declined from -$0.7776 to -$0.7885.
Kymera Therapeutics, Inc. (KYMR) was downgraded to D- from D on 2/8/2023 due to a decline in the growth index and valuation index. Total revenue declined 17.05% from $11.51M to $9.55M, EBIT declined 9.98% from -$40.81M to -$44.88M, and earnings per share declined from -$0.7776 to -$0.7885.
D
Sell
9/9/2022Upgraded
Kymera Therapeutics, Inc. (KYMR) was upgraded to D from D- on 9/9/2022 due to an increase in the total return index and volatility index.
Kymera Therapeutics, Inc. (KYMR) was upgraded to D from D- on 9/9/2022 due to an increase in the total return index and volatility index.
D
Sell
8/10/2022Downgrade
Kymera Therapeutics, Inc. (KYMR) was downgraded to D- from D on 8/10/2022 due to a noticeable decline in the total return index, growth index and solvency index. EBIT declined 10.5% from -$36.93M to -$40.81M, earnings per share declined from -$0.7102 to -$0.7776, and the quick ratio declined from 4.78 to 4.51.
Kymera Therapeutics, Inc. (KYMR) was downgraded to D- from D on 8/10/2022 due to a noticeable decline in the total return index, growth index and solvency index. EBIT declined 10.5% from -$36.93M to -$40.81M, earnings per share declined from -$0.7102 to -$0.7776, and the quick ratio declined from 4.78 to 4.51.
D
Sell
5/4/2022Upgraded
Kymera Therapeutics, Inc. (KYMR) was upgraded to D from E+ on 5/4/2022 due to an increase in the valuation index.
Kymera Therapeutics, Inc. (KYMR) was upgraded to D from E+ on 5/4/2022 due to an increase in the valuation index.
E
Sell
5/1/2022Downgrade
Kymera Therapeutics, Inc. (KYMR) was downgraded to E+ from D on 5/1/2022 due to a decline in the total return index and volatility index.
Kymera Therapeutics, Inc. (KYMR) was downgraded to E+ from D on 5/1/2022 due to a decline in the total return index and volatility index.
D
Sell
4/21/2022Upgraded
Kymera Therapeutics, Inc. (KYMR) was upgraded to D from E+ on 4/21/2022 due to an increase in the valuation index.
Kymera Therapeutics, Inc. (KYMR) was upgraded to D from E+ on 4/21/2022 due to an increase in the valuation index.
E
Sell
4/20/2022Downgrade
Kymera Therapeutics, Inc. (KYMR) was downgraded to E+ from D on 4/20/2022 due to a substantial decline in the total return index, volatility index and growth index. Total revenue declined 24.89% from $20.34M to $15.28M, EBIT declined 18.71% from -$28.64M to -$33.99M, and earnings per share declined from -$0.5636 to -$0.6596.
Kymera Therapeutics, Inc. (KYMR) was downgraded to E+ from D on 4/20/2022 due to a substantial decline in the total return index, volatility index and growth index. Total revenue declined 24.89% from $20.34M to $15.28M, EBIT declined 18.71% from -$28.64M to -$33.99M, and earnings per share declined from -$0.5636 to -$0.6596.
D
Sell
11/9/2021Upgraded
Kymera Therapeutics, Inc. (KYMR) was upgraded to D from E+ on 11/9/2021 due to an increase in the total return index.
Kymera Therapeutics, Inc. (KYMR) was upgraded to D from E+ on 11/9/2021 due to an increase in the total return index.
E
Sell
11/8/2021Downgrade
Kymera Therapeutics, Inc. (KYMR) was downgraded to E+ from D on 11/8/2021 due to a decline in the volatility index, valuation index and solvency index.
Kymera Therapeutics, Inc. (KYMR) was downgraded to E+ from D on 11/8/2021 due to a decline in the volatility index, valuation index and solvency index.
D
Sell
3/24/2021Downgrade
Kymera Therapeutics, Inc. (KYMR) was downgraded to D from D+ on 3/24/2021 due to a substantial decline in the efficiency index, volatility index and growth index. Operating cash flow declined 115.24% from $131.67M to -$20.07M, net income declined 58.84% from -$7.99M to -$12.69M, and EBIT declined 58.13% from -$8.08M to -$12.78M.
Kymera Therapeutics, Inc. (KYMR) was downgraded to D from D+ on 3/24/2021 due to a substantial decline in the efficiency index, volatility index and growth index. Operating cash flow declined 115.24% from $131.67M to -$20.07M, net income declined 58.84% from -$7.99M to -$12.69M, and EBIT declined 58.13% from -$8.08M to -$12.78M.
D
Sell
11/16/2020None
Kymera Therapeutics, Inc. (KYMR) was downgraded to D+ from U on 11/16/2020.
Kymera Therapeutics, Inc. (KYMR) was downgraded to D+ from U on 11/16/2020.
NASDAQ
04/04/2025 12:58PM Eastern
Quotes delayed
